Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Valeant Finalizing Contract with Perrigo’s CEO

By AP | April 22, 2016

NEW YORK (AP) — The over-the-counter drugmaker Perrigo says it’s aware of media reports that its CEO will take the top job at troubled Valeant Pharmaceuticals, but it won’t confirm those reports.

The Wall Street Journal reported Thursday that Valeant is finalizing a contract with Perrigo Chairman and CEO Joseph C. Papa and could announced the hire as early as next week.

In this March 15, 2016 file photo, a trading post on the floor of the New York Stock Exchange displays the Valeant Pharmaceuticals logo. The Wall Street Journal reported Thursday, April 21, 2016, that Valeant is finalizing a contract with Perrigo Chairman and CEO Joseph C. Papa and could announced the hire as early as next week. Perrigo said Friday that it would not comment on “speculation or market rumor.” (AP Photo/Richard Drew)

Perrigo said Friday that it would not comment on “speculation or market rumor.”

Valeant is under heavy scrutiny in the U.S. for its strategy of buying small drugmakers, then raising prices sharply on older, off-patent drugs.

In March, Valeant said it would replace CEO Michael Pearson after billions evaporated from the company’s worth.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE